3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
2433
Neoplasms
1842
Carcinoma, Non-Small-Cell Lung
1609
Prostatic Neoplasms
1312
Colorectal Neoplasms
1144
Lung Neoplasms
991
Neoplasm Metastasis
835
Multiple Myeloma
800
Leukemia, Myeloid, Acute
778
Ovarian Neoplasms
685
Pancreatic Neoplasms
671
Melanoma
667
Squamous Cell Carcinoma of Head and Neck
592
Carcinoma, Hepatocellular
570
Recurrence
568
Brain Neoplasms
528
Glioblastoma
519
Stomach Neoplasms
503
Head and Neck Neoplasms
502
Triple Negative Breast Neoplasms
473
Lymphoma
461
Uterine Cervical Neoplasms
457
Carcinoma, Renal Cell
429
Precursor Cell Lymphoblastic Leukemia-Lymphoma
421
Lymphoma, Non-Hodgkin
390
Endometrial Neoplasms
386
Sarcoma
369
Urinary Bladder Neoplasms
356
Lymphoma, Large B-Cell, Diffuse
356
Lymphoma, Follicular
356
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
1 year
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled